As President Trump’s 100% tariffs on patented imported drugs face delays, the silence from U.S. Customs and Border Protection underscores the profound complexities in distinguishing pharmaceutical products and the wider implications for drug affordability, domestic manufacturing, and the stability of the nation’s healthcare supply chain.
In a bold move intended to reshape the American pharmaceutical landscape, President Trump announced in late September a plan for a sweeping 100% tariff on imported patented drugs, initially set to commence on October 1. This ambitious directive aimed to incentivize domestic production, fortify U.S. supply chains, and, according to the president, potentially lower drug costs. However, the plan was quickly put on hold as the administration engaged in negotiations, reportedly striking deals with at least two drug companies, as reported by The Center Square.
CBP’s Conundrum: Identifying Patented vs. Generic Imports
The practicalities of implementing such a specific tariff quickly surfaced as a significant hurdle. U.S. Customs and Border Protection (CBP), the federal agency tasked with collecting tariff revenue, has remained notably silent on its preparations. When The Center Square inquired about how CBP would identify patented pharmaceutical drugs, distinguish them from generic alternatives for tariff collection, prepare for enforcement, and manage exemption lists, a spokesperson offered no comment. This silence, amid a partial government shutdown that commenced on October 1, highlights the profound logistical challenges inherent in the president’s directive.
The core issue lies in the granular distinction between patented and generic drugs. The Harmonized Tariff Schedule of the United States (HTSUS) provides a comprehensive framework for classifying imported goods. While it details numerous categories for “medicaments,” these classifications typically focus on chemical composition and dosage form, rather than intellectual property status like patent protection. This presents a novel challenge for CBP, which historically hasn’t needed to make such distinctions for tariff purposes.
The Harmonized Tariff Schedule: A Glimpse into Drug Classification
To illustrate how drugs are typically classified, consider a specific example from a CBP tariff classification ruling. Metronidazole for injection, imported in dosage form, is assigned to HTSUS subheading 3004.90.9208, which describes “medicaments…consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses…or in forms or packings for retail sale: other: other: other: anti-infective medicaments: antiprotozoals (excluding goods described in subheading note 2 to this chapter): containing metronidazole or its salts.” The duty rate for this particular product was listed as free, as detailed in a ruling published by U.S. Customs and Border Protection. This example demonstrates the detailed nature of drug classification under the HTSUS but also reveals that the primary classification mechanism does not inherently differentiate between patented and generic status, posing a significant operational hurdle for the proposed tariffs.
Historical Precedent: Tariffs Beyond Economic Measures
While President Trump’s proposed tariffs are unique in their focus on patented drugs for economic and supply chain reasons, the U.S. has a history of using tariffs related to pharmaceutical products for different policy goals. For instance, Title 19, Chapter 12 of the U.S. Code, Section 2492, outlines specific “Tariff treatment of products of uncooperative major drug producing or drug-transit countries.” This legislation, dating back to 1986, empowers the President to deny preferential tariff treatment or apply additional duties of up to 50% ad valorem on products from countries deemed uncooperative in combating international drug trafficking, according to the U.S. House of Representatives Office of the Law Revision Counsel. This historical context highlights the U.S. government’s prior use of tariffs as a foreign policy tool in the drug sector, albeit with a different motivation—combating illicit drug trade—than the current proposal’s focus on domestic manufacturing and supply chain resilience.
Industry and Healthcare Sound the Alarm
The pharmaceutical industry and healthcare providers have voiced considerable concerns regarding the potential implications of these tariffs. The American Hospital Association (AHA), in comments submitted to the Department of Commerce, warned about significant supply issues. They urged the administration to maintain tariff exceptions, especially for products already facing shortages and for countries that are crucial suppliers to the U.S. market. The AHA emphasized the critical role of readily available drugs for patients facing emergent and critical conditions, stating that “The lives of patients often depend on the ready availability of drugs to respond to emergent conditions like heart attacks and infections, and other critical illnesses like cancer and organ failure.”
Monica Gorman, who served as special assistant to the president for manufacturing and industrial policy and co-chair of the White House Supply Chain Disruptions Task Force from 2022-25, offered a crucial perspective. She pointed out that more than 90% of U.S. prescriptions are filled with generic drugs. Since Trump’s tariffs specifically target patented drug imports, most Americans might not experience a direct impact at the pharmacy counter, Gorman told The Center Square.
Conversely, Alex Schriver, senior vice president of Pharmaceutical Research and Manufacturers of America (PhRMA), argued that funds allocated to tariffs would be diverted from vital investments in innovation. “Every dollar spent on tariffs is a dollar that cannot be invested in American manufacturing or the development of future treatments and cures,” Schriver stated, highlighting the industry’s concern over the potential long-term impact on research and development.
Looking Ahead: The Future of Pharmaceutical Tariffs
The delay in implementing President Trump’s 100% tariffs on patented drugs indicates the significant complexity of such a policy. Beyond the immediate economic impact, the proposal raises fundamental questions about the government’s capacity to enforce highly specific trade policies within intricate global supply chains. The ongoing discussions with drug companies and the sustained silence from CBP suggest a challenging road ahead for any broad implementation of these tariffs. As the pharmaceutical sector continues to evolve, stakeholders will closely watch how the balance between fostering domestic production, ensuring patient access, and maintaining global innovation is navigated in this complex policy environment.
